Gland Pharma Share Price

NSE: GLAND

₹ 2,388.00

+₹10.30 (0.43%)

Last updated 24 Jul, 2026, 15:29 IST

Gland Pharma Share Price Today

As of 26 Jul 2026, Gland Pharma share price is ₹2,388.00. The stock opened at ₹2,379.00, compared to its previous close of ₹2,377.70. During today's trading session, Gland Pharma share price moved in the range of ₹2,366.20 to ₹2,415.00, with an average price of ₹2,390.60 for the day. Looking at its last 52-week, the stock has touched a low of ₹1,573.60 and a high of ₹2,573.50. On the performance front, Gland Pharma share price has increased by 41.44% over the last six months and is up 17.92% on a year-on-year basis.

₹2,366.20

0.43% up today

₹2,415.00

1D LOW

1D HIGH

Latest Earning

Op Profit TrendUp by 39.67% QoQ

Latest Earning

Net Profit TrendUp by 40.23% QoQ

Latest Earning

Revenue TrendUp by 5.44% QoQ

Stock Performance

OutperformingBeat Nifty by 3.36 % in last 1 month

Shareholding Pattern

PromoterPromoter decreased stake by 0.12%

Shareholding Pattern

DIIDII increased stake by 40.05%

Shareholding Pattern

FIIFII increased stake by 19.76%

Gland Pharma Returns Calculator

If you would've invested

₹

₹1,000₹1Cr

Historical Returns

1 Year

₹5,89,556+₹89,556 (+17.91%)

3 Year

₹9,10,023+₹4,10,023 (+82.00%)

5 Year

₹3,02,739-₹1,97,261 (-39.45%)

₹1,903.90₹2,855.70

Circuit Low

Circuit High

₹1,573.60₹2,573.50

52-Week Low

52-Week High

Circuit

₹1,903.90

₹2,855.70

52-week

₹1,573.60

₹2,573.50

Mkt Cap Cr

39,233.20

P/E

38.19

P/B

3.79

ROE

9.92%

D/E

0.00

ROCE

14.02%

Div. Yield

0.84%

EPS(TTM)

78.88

Turnover

0.41

EV/EBITDA

18.81

Net Margin

0.00%

Op. Margin

0.00%

ROA

8.21%

Quick Ratio

0.00

Curr. Ratio

10.15

Mkt Cap Cr

39,233.20

P/E

38.19

P/B

3.79

ROE

9.92%

D/E

0.00

ROCE

14.02%

Div. Yield

0.84%

EPS(TTM)

78.88

Turnover

0.41

EV/EBITDA

18.81

Net Margin

0.00%

Op. Margin

0.00%

ROA

8.21%

Quick Ratio

0.00

Curr. Ratio

10.15

Based on fundamentals, this stock's

Performance

Excellent

Gland Pharma outperforming all market indices

Valuation

Overvalued

Gland Pharma appears overvalued compared to its peers

Earnings

Excellent

Gland Pharma revenue, operating profit and net profit are growing

Peer Comparison

Peer comparison — key ratios
Name	Mkt Cap Cr	P/E	P/B	ROE	D/E	ROCE	Book Value	Div. Yield	Turnover	EPS(TTM)
Sun Pharmaceutical Industries	4,65,711.00	36.73	5.05	14.85%	0.55	18.72%	18.85	0.91%	0.56	10.90
Divis Laboratories	1,92,376.00	61.36	9.40	16.19%	0.00	21.00%	9.43	0.50%	0.58	98.19
Torrent Pharmaceuticals	1,88,655.00	66.03	17.03	26.76%	1.05	18.30%	16.90	0.90%	0.49	64.75
Cipla	1,13,979.00	33.96	3.31	11.27%	0.00	14.95%	423.36	0.92%	0.45	43.52
Zydus Lifesciences	1,10,613.00	17.39	3.23	19.69%	0.35	20.30%	3.70	0.11%	0.39	35.38
Lupin	1,08,339.00	19.83	4.71	27.01%	0.03	27.44%	3.51	0.78%	0.61	129.18
Mankind Pharma	1,03,472.00	1.05	0.12	12.65%	0.42	12.97%	5.05	0.05%	0.54	49.37
Dr. Reddy's Laboratories	96,204.70	30.22	2.53	11.07%	0.18	12.54%	377.96	0.69%	0.41	38.68
Aurobindo Pharma	88,949.80	25.39	2.35	9.25%	0.19	11.76%	391.14	0.26%	0.48	41.58
Laurus Labs	86,564.20	79.36	16.33	16.77%	0.40	16.14%	97.21	0.12%	0.67	13.72

Gland Pharma Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
Particulars	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Revenue	₹5,616.50	₹5,664.72	₹3,624.60	₹4,400.71
Other Income	₹213.61	₹170.24	₹240.46	₹223.94
Total Revenue	₹5,830.11	₹5,834.96	₹3,865.06	₹4,624.65
Total Expenses	₹4,767.45	₹4,702.42	₹2,754.02	₹3,006.09
Profit Before Tax	₹1,062.66	₹1,132.54	₹1,054.58	₹1,618.55
Tax	₹364.13	₹360.08	₹273.54	₹406.89
Profit After Tax	₹698.53	₹772.46	₹781.04	₹1,211.66
EPS - Basic	₹42.40	₹46.90	₹47.44	₹73.81
EPS - Diluted	₹42.40	₹46.89	₹47.43	₹73.64

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
Particulars	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Profit before tax	₹1,062.66	₹1,132.54	₹1,054.58	₹1,618.55
Income before WC changes	₹1,274.60	₹1,356.15	₹1,092.77	₹1,590.36
Change in Assets	-₹141.92	₹336.02	-₹579.66	-₹468.36
Change in Liabilities	₹135.86	-₹389.22	₹161.72	₹75.28
Change in WC	-₹6.06	-₹53.20	-₹417.94	-₹393.08
Cash flow from Operations	₹914.73	₹996.80	₹363.97	₹790.77
Cash flow from Investing	₹1,704.74	-₹1,756.91	₹1,208.19	-₹1,002.62
Cash flow from Financing	-₹433.48	-₹799.42	₹14.92	₹34.90
Total Cash Flow	₹2,185.99	-₹1,559.53	₹1,587.08	-₹176.95
Cash (Start of the year)	₹357.09	₹1,908.90	₹318.82	₹492.46
Cash (End of the year)	₹2,556.21	₹357.09	₹1,908.90	₹318.82

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
Particulars	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Non-Current Assets	₹4,441.98	₹5,016.09	₹1,876.73	₹1,981.54
Current Assets	₹6,782.94	₹5,645.15	₹6,900.81	₹5,852.08
Total Assets	₹11,224.92	₹10,661.25	₹8,777.54	₹7,833.62
Current Liabilities	₹1,564.85	₹1,398.36	₹729.13	₹582.03
Net Current Asset	₹5,218.09	₹4,246.79	₹6,171.68	₹5,270.05
Non-Current Liabilities	₹509.33	₹539.04	₹89.68	₹93.98
Equity Capital	₹9,150.74	₹8,723.84	₹7,958.72	₹7,157.62
Total Equity & Liabilities	₹11,224.92	₹10,661.25	₹8,777.54	₹7,833.62

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
Particulars	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Revenue	₹4,116.15	₹4,167.43	₹3,616.53	₹4,400.71
Other Income	₹215.08	₹166.67	₹240.46	₹223.94
Total Revenue	₹4,331.22	₹4,334.09	₹3,856.99	₹4,624.65
Total Expenses	₹2,865.64	₹2,928.60	₹2,752.13	₹3,005.61
Profit Before Tax	₹1,465.59	₹1,405.50	₹1,048.40	₹1,619.04
Tax	₹375.83	₹362.17	₹272.58	₹406.89
Profit After Tax	₹1,089.75	₹1,043.33	₹775.83	₹1,212.16
EPS - Basic	₹66.15	₹63.35	₹47.12	₹73.84
EPS - Diluted	₹66.15	₹63.33	₹47.11	₹73.67

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
Particulars	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Profit before tax	₹1,465.59	₹1,405.50	₹1,048.40	₹1,619.04
Income before WC changes	₹1,460.43	₹1,428.65	₹1,085.78	₹1,590.85
Change in Assets	-₹121.33	₹343.35	-₹570.86	-₹468.39
Change in Liabilities	₹86.74	-₹319.97	₹163.86	₹75.34
Change in WC	-₹34.59	₹23.38	-₹407.00	-₹393.05
Cash flow from Operations	₹1,073.67	₹1,135.97	₹367.89	₹791.29
Cash flow from Investing	₹1,578.20	-₹2,923.92	₹1,208.22	-₹1,010.23
Cash flow from Financing	-₹339.54	-₹7.40	₹14.92	₹34.90
Total Cash Flow	₹2,312.33	-₹1,795.35	₹1,591.04	-₹184.04
Cash (Start of the year)	₹116.21	₹1,905.22	₹311.18	₹491.92
Cash (End of the year)	₹2,432.62	₹116.21	₹1,905.22	₹311.18

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
Particulars	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Non-Current Assets	₹4,654.66	₹4,969.76	₹1,884.84	₹1,989.70
Current Assets	₹5,766.96	₹4,571.33	₹6,888.34	₹5,844.44
Total Assets	₹10,421.62	₹9,541.09	₹8,773.18	₹7,834.14
Current Liabilities	₹523.77	₹414.20	₹730.20	₹581.94
Net Current Asset	₹5,243.20	₹4,157.13	₹6,158.14	₹5,262.50
Non-Current Liabilities	₹142.75	₹131.60	₹89.68	₹93.98
Equity Capital	₹9,755.10	₹8,995.29	₹7,953.30	₹7,158.23
Total Equity & Liabilities	₹10,421.62	₹9,541.09	₹8,773.18	₹7,834.14

* All values are in INR Crore

Qty

Bid

Ask

Qty

2379.8

Bid Total: 0

Ask Total: 5

Buy orders: 0%

Sell orders: 100%

30 levels of bid & ask depth

Supply & Demand Zones

Bearish

Neutral

Bullish

Slightly Bullish

by SEBI experts available for this stock

Earn more using advisory

by SEBI experts

Expert Pick

EXPPICK

Stop-loss

Entry price

Target

Indicator

Value

Verdict

RSI (14)

48.15

Neutral

ATR (14)

83.59

Neutral

STOCH(9,6)

13.43

Bullish

STOCH RSI (14)

0.85

Bullish

ADX(9)

34.03

Bearish

UO(9)

46.79

Neutral

ROC(12)

-4.65

Bearish

WillR(14)

-87.1

Bullish

Period

Simple value

Exponential vaue

2427.62

2416.4

10D

2453.11

2435.79

20D

2461.54

2422.2

50D

2325.6

2298.46

100D

2033.13

2137.7

About Gland Pharma

ISIN

INE068V01023

Sector Market Cap

₹ 39,233.2 Cr

Gland Pharma Limited is an India-based generic injectables manufacturer. The Company specializes in sterile injectables, oncology, and ophthalmic, with a specific focus on complex injectables, New Chemical Entities (NCE)-1s, First-to-File products, and 505(b)(2) filings. The Company manufactures a range of dosage formulations, including solutions, suspensions, and lyophilized products. Its product portfolio includes delivery methods such as pre-filled syringes, vials, ampoules, bags, and dry powder injections. It also produces generic injectables in liquid, lyophilized, suspension, and pre-filled syringe forms. Its molecules include Enoxaparin Sodium, Cisplatin, Lacosamide, Rocuronium Bromide, Zoledronic Acid, Vancomycin, and others. Its therapeutic products categories include Anti Malarials, Anti-Infectives, Anti-Neoplastics, Gynecological, Hormones, and others. The Company functions primarily on a business-to-business model. Its subsidiary is Gland Pharma International Pte. Ltd.

Gland Pharma Financial Highlights

Revenue: Gland Pharma reported revenue of ₹6,746.98 crore in FY26 vs ₹5,830.11 crore in FY25. It showed an increase of 15.73% on a yearly basis.
Operating Profit: Gland Pharma reported an operating profit of ₹1,464.58 crore in FY26 vs ₹1,062.66 crore in FY25. It showed an increase of 37.82% on a year-on-year basis.
Net Profit: Gland Pharma reported a net profit of ₹1,027.32 crore in FY26 vs ₹698.53 crore in FY25. It showed an increase of 47.07% on a yearly basis.

Gland Pharma Quarterly Result Highlights

Gland Pharma reported revenue of ₹1,854.26 crore in Mar 2026, compared with ₹1,758.53 crore in Dec 2025, representing an increase of 5.44% on a quarter-on-quarter (QoQ) basis.
Gland Pharma reported an operating profit of ₹505.80 crore in Mar 2026, compared with ₹362.13 crore in Dec 2025, representing an increase of 39.67% on a quarter-on-quarter (QoQ) basis.
Gland Pharma reported a profit of ₹366.68 crore in Mar 2026, compared with ₹261.48 crore in Dec 2025, reflecting an increase of 40.23% on a QoQ basis.
The earnings per share (EPS) of Gland Pharma stood at ₹42.40 during Mar 2026.